Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Duchenne muscular dystrophy (DMD) is a lethal muscle disease for which an effective treatment is urgently needed. The use of stem cells to produce normal muscle cells to replace the missing dystrophin protein has attracted much attention. Claims of success using stem cell treatment in animal models of human muscle diseases require careful evaluation and are not necessarily easily extrapolated to the clinical situation. Recent studies in the dystrophic dog model have been claimed to show that injected mesangioblasts, stem cells derived from blood vessels, reduce the severity of the disease. However, the authors' interpretation of the results did not consider that benefits might arise from the concomitant use of immunosuppressive drugs alone.

Original publication




Journal article


Neuromuscul Disord

Publication Date





206 - 208


Animals, Humans, Immunosuppressive Agents, Muscular Dystrophy, Duchenne, Stem Cell Transplantation, Stem Cells